Stephen John Freese

Title: **Stephen John Freese: Innovator in Immunogenic Conjugates**

Introduction

Stephen John Freese, an accomplished inventor located in Cornwall-on-Hudson, NY, has made significant contributions to the field of immunology through his innovative work. With a total of two patents to his name, Freese is recognized for his groundbreaking research and development of immunogenic conjugates.

Latest Patents

Stephen John Freese's latest patents focus on immunogenic conjugates that incorporate serotype 5 and 8 capsular polysaccharides conjugated to carrier proteins. These patents detail methods for preparing these conjugates, which involve the covalent bonding of capsular polysaccharides with carrier proteins utilizing specific conjugation chemistry techniques. The methods employ reagents such as 1,1-carbonyl-di-1,2,4-triazole (CDT) and 3-(2-pyridyldithio)-propionyl hydrazide (PDPH). This innovative approach aims to enhance the immunogenic properties of the conjugates for potential applications in vaccines.

Career Highlights

Stephen is currently associated with Wyeth, a prominent biopharmaceutical company known for its focus on various therapeutic areas, including immunology. His work at Wyeth has allowed him to collaborate with leading experts in the field, driving forward essential research initiatives centered around immunogenic therapies.

Collaborations

Freese's collaborative efforts include working alongside notable colleagues such as Annaliesa Sybil Anderson and Viliam Pavliak. Together, they have contributed to advancing research in immunogenic conjugates, fostering an environment of innovation and shared knowledge within their team.

Conclusion

Through his innovative patents and collaborative spirit, Stephen John Freese continues to make significant strides in the realm of immunology. His contributions to the development of immunogenic conjugates not only underline his expertise as an inventor but also hold promise for future advancements in vaccine technology.